Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;138(3):949-57.e1-7.
doi: 10.1053/j.gastro.2009.11.010. Epub 2009 Nov 18.

Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer

Lei Zhang  1 , James J Farrell, Hui Zhou, David Elashoff, David Akin, No-Hee Park, David Chia, David T Wong
Affiliations

Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer

Lei Zhang et al. Gastroenterology. 2010 Mar.

Abstract

Background & aims: Lack of detection technology for early pancreatic cancer invariably leads to a typical clinical presentation of incurable disease at initial diagnosis. New strategies and biomarkers for early detection are sorely needed. In this study, we have conducted a prospective sample collection and retrospective blinded validation to evaluate the performance and translational utilities of salivary transcriptomic biomarkers for the noninvasive detection of resectable pancreatic cancer.

Methods: The Affymetrix HG U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA) was used to profile transcriptomes and discover altered gene expression in saliva supernatant. Biomarkers discovered from the microarray study were subjected to clinical validation using an independent sample set of 30 pancreatic cancer patients, 30 chronic pancreatitis patients, and 30 healthy controls.

Results: Twelve messenger RNA biomarkers were discovered and validated. The logistic regression model with the combination of 4 messenger RNA biomarkers (KRAS, MBD3L2, ACRV1, and DPM1) could differentiate pancreatic cancer patients from noncancer subjects (chronic pancreatitis and healthy control), yielding a receiver operating characteristic plot, area under the curve value of 0.971 with 90.0% sensitivity and 95.0% specificity.

Conclusions: The salivary biomarkers possess discriminatory power for the detection of resectable pancreatic cancer, with high specificity and sensitivity. This report provides the proof of concept of salivary biomarkers for the noninvasive detection of a systemic cancer and paves the way for prediction model validation study followed by pivotal clinical validation.

PubMed Disclaimer

Conflict of interest statement

Disclosures: The authors have declared that no competing interests and potential conflicts exist.

Figures

Figure 1
Figure 1
Schematic of the Strategy Used for the Discovery and Validation of Salivary Biomarkers. PC: pancreatic cancer; H: healthy control; CP: chronic pancreatitis.
Figure 2
Figure 2
Heatmap of 35 qPCR verified genes (23 up-regulated and 12 down-regulated) based on the microarray data. Hierarchical clustering and gene function enrichment was performed using Euclidean distance metric and Centroid linkage method (unsupervised clustering). Pancreatic cancer patients (n=12) and healthy controls (n=12) could be classified into distinct groups, indicating the discriminatory power of salivary mRNA biomarkers. The GEO database access number of all microarray experiments is GSE14245.
Figure 3
Figure 3
ROC curve and Interactive dot diagram for the logistic regression model. (A) The logistic regression model using four biomarkers (KRAS, MBD3L2, ACRV1 and DPM1) yielded an AUC value of 0.971 (cutoff 0.433). (B) Interactive dot diagram was based on the qPCR data of the non-cancer group (n = 60) and cancer group (n = 30).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, Fishman EK, Brune K, Axilbund J, Griffin C, Ali S, Richman J, Jagannath S, Kantsevoy SV, Kalloo AN. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766–81. quiz 665. - PubMed
    1. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, Ali SZ, Jagannath S, Petersen GM, Fishman EK, Piantadosi S, Giardiello FM, Hruban RH. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606–21. - PubMed
    1. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc. 2003;57:23–9. - PubMed
    1. Hoimes CJ, Moyer MT, Saif MW. Biomarkers for early detection and screening in pancreatic cancer. JOP; Highlights from the 45th ASCO annual meeting; Orlando, FL, USA. May 29–June 2, 2009; 2009. pp. 352–6. - PubMed
    1. Farrell JJ, van Rijnsoever M, Elsaleh H. Early detection markers in Pancreas Cancer. Cancer Biomark. 2005;1:157–75. - PubMed

Publication types

MeSH terms

Associated data